secwatch.observer — SEC 8-K summary
======================================

Issuer:     iBio, Inc. (IBIO)
CIK:        0001420720
Form:       8-K
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001104659-26-040703
Event type: regulatory
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

iBio gets TGA/ethics approval for IBIO-600 Phase 1; warrants expire May 12
--------------------------------------------------------------------------

- Received CTN acknowledgement from Australia's TGA and ethics committee approval to initiate first-in-human Phase 1 trial of IBIO-600.
- First participant dosing expected in second quarter 2026.
- IBIO-600 is a long-acting anti-myostatin monoclonal antibody designed to preserve lean mass in obesity, with potential for 2-4 doses per year.
- Series G warrants (outstanding ~27.9M shares) will expire on May 12, 2026 – 30 trading days after this public announcement.
- If all Series G warrants exercised, an additional ~27.9M common shares issued plus Series H warrants for same amount.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926040703/0001104659-26-040703-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1420720/000110465926040703/ibio-20260408x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-040703

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer